Global biotech giant Shire Group (LON:SHP ) has this morning reported that its innovative preventative treatment for hereditary angiodema, Takhzyro, has received approval from the Food and Drug Administration.Takhzyro is a self administered, sub-cutaneous injection which studies have shown to reduce average monthly attacks by 87 per cent, compared with a placebo group. Furthermore, a significant number of the experimental group suffered from zero attacks during the trial.
The news has impacted positively on Shire’s share price which was up 104.50 (2.36%) as of BST 08.58 to 4527.00 and climbing, overperforming the FTSE which in comparison is marginally up 10.86 (0.14%) at 7574.08, possibly subdued following an escalation in the US/China trade stand off.
Aim for zero attacks
In a press release from the group, Andreas Busch, Phd., Head of Research and Development for the company said, “With the approval of Takhzyro, HAE patients have an innovative treatment that works differently to current options to help prevent attacks. Based on an exploratory and post hoc analysis, after six doses of Takhzyro 300mg every two weeks, 77% or nearly 8 out of 10 patients had zero attacks. This approval reinforces our ongoing commitment to developing novel therapies that have a meaningful impact on patients. Looking to the future we continue to work towards our goal of a world in which those living with HAE can aim for zero attacks.”
Recurring edema can be fatal
HAE is a genetic disorder which is thought to affect somewhere in the region of 1 in 10,000 to 1 in 50,000 people. The condition manifests itself in extremely debilitating, painful, recurring edema which predominantly affects the face,hands and airways, and can be fatal if experienced in the larynx, causing asphyxiation.
In response to the news, as reported by Proactive Investors, Anthony Castaldo, president of the US Hereditory Angiodema Association marked the findings of the study as an : “…important addition to the HAE treatment landscape.”